Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Epicardial adipose tissue (EAT) is an easily measurable visceral fat of the heart with unique anatomy, functionality, and transcriptome. EAT can serve as a therapeutic target for pharmaceutical agents targeting the fat. Glucagon-like peptide-1 (GLP-1) and GLP-2 analogues are newer drugs showing beneficial cardiovascular and metabolic effects. Whether EAT expresses GLP- 1 and 2 receptors (GLP-1R and GLP-2R) is unknown. RNA-seq analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to evaluate the presence of GLP-1R and GLP-2R in EAT and subcutaneous fat (SAT) obtained from 8 subjects with coronary artery disease and type 2 diabetes mellitus undergoing elective cardiac surgery. Immunofluorescence was also performed on EAT and SAT samples using Mab3f52 against GLP-1R. Our RNA-sequencing (RNA-seq) analysis showed that EAT expresses both GLP-1R and GLP-2R genes. qRT-PCR analysis confirmed that GLP-1R expression was low but detected by 2 different sets of intron-spanning primers. GLP-2R expression was detected in all patients and was found to be 5-fold higher than GLP-1R. The combination of accurately spliced reads from RNA-seq and successful amplification using intron-spanning primers indicates that both GLP-1R and GLP-2R are expressed in EAT. Immunofluorescence clearly showed that GLP-1R is present and more abundant in EAT than SAT. This is the first time that human EAT is found to express both GLP-1R and GLP-2R genes. Pharmacologically targeting EAT may induce beneficial cardiovascular and metabolic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The epicardial AT, the heart’s counterpart in visceral fat, was found to express GLP-1R [69].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Remarkably, human EAT expressed the GLP-1 receptor (GLP-1R) gene and protein, suggesting that EAT reduction can be mediated by a direct effect and activation of GLP-1R [18].”
From Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity (2020) · cites this paper as [18]
In the citing paper
“Examining RNA-sequencing data from EAT samples obtained during elective cardiothoracic surgery in 5 T2DM patients with CAD and 3 nondiabetic subjects, Iacobellis et al. demonstrated that human EAT expresses both GLP-1R and GLP-2R genes without differences related to co-morbid diabetes [179].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [179]
In the citing paper
“GLP-1 receptor is expressed in the adipose tissue and mRNA, and protein expressions are increased in epicardial and other visceral fat [18, 24, 28, 29].”
From Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity (2020) · cites this paper as [18]
In the citing paper
“suggesting that EAT reduction can be mediated by a direct effect and activation of GLP-1R [18].”
From Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity (2020) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“org) and quantified using the STAR aligner [11].”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Human epicardial adipose tissue is a source of inflammatory mediators
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O’Brien, S., Keiper, E. A., Johnson, A. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000099542.57313.c5 · Cited by 1,966 · cited 1×
“EAT exerts its atherogenic action through the paracrine secretion of pro-inflammatory cytokines, upregulated in this fat depot [2, 20].”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 2×
“This antibody has been extensively validated to show its specificity [13, 14].”
BackgroundIacobellis, G., Ribaudo, M. C., Assael, F., Vecci, E., Tiberti, C., Zappaterreno, A., Di Mario, U., & Leonetti, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030698 · Cited by 842 · cited 1×
“Epicardial fat is an easily measurable risk factor [15, 16] that has shown to significantly respond to thiazolidinediones, insulin, dipeptidyl peptidase-4 inhibitors and statins [17–19].”
BackgroundSelf-citationLocal and systemic effects of the multifaceted epicardial adipose tissue depot
Iacobellis, G. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.58 · Cited by 605 · cited 2×
“Excessive EAT accumulation has been largely associated with higher cardiovascular risk [1].”
BackgroundSelf-citationGLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“GLP-1 activation may also stimulate browing thermogenesis of EAT [22] and therefore restore its physiological role of providing heat to the myocardium [23].”
BackgroundSacks, H. S., Fain, J. N., Holman, B., Cheema, P., Chary, A., Parks, F., Karas, J., Optican, R., Bahouth, S. W., Garrett, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0571 · Cited by 320
Liraglutide causes large and rapid epicardial fat reduction
Iacobellis, G., Mohseni, M., Bianco, S. D., & Banga, P. K. (2017) · Obesity · doi:10.1002/oby.21718 · Cited by 251 · cited 5×
“glutide causes a substantial and rapid EAT reduction in subjects with diabetes and obesity [7].”
BackgroundInfluentialSelf-citationVendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · cited 3×
“Moreover, recent experimental data suggest that glucagon-like peptide 2 (GLP-2) may produce beneficial effects on glucose metabolism in obese animal models [8, 9].”
BackgroundGubern, C., Hurtado, O., Rodríguez-Romanos, R., Morales, J. R., Romera, V. G., Moro, M. Á., Lizasoaín, I., Serena, J. L., & Mallolas, J. (2009) · BMC Molecular Biology · doi:10.1186/1471-2199-10-57 · Cited by 160 · cited 1×
“Furthermore, other studies have investigated the stability of many housekeeping genes and found that SDHA is more stable than other commonly used reference genes [12].”
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · cited 2×
“This antibody has been extensively validated to show its specificity [13, 14].”
BackgroundEpicardial adipose tissue has a unique transcriptome modified in severe coronary artery disease
McAninch, E. A., Fonseca, T. L., Poggioli, R., Panos, A. L., Salerno, T. A., Deng, Y., Li, Y., Bianco, A. C., & Iacobellis, G. (2015) · Obesity · doi:10.1002/oby.21059 · Cited by 130
Self-citationMorano, S., Romagnoli, E., Filardi, T., Nieddu, L., Mandosi, E., Fallarino, M., Turinese, I., Dagostino, M. P., Lenzi, A., & Carnevale, V. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0710-z · Cited by 110 · cited 2×
“Exenatide, and mostly liraglutide, 2 widely used GLP-1 analogues, have also shown to significantly reduce EAT [6, 7], independently of weight loss and glucose control, arising therefore the question of a possible specific drug-effect.”
BackgroundResultEpicardial fat: a new cardiovascular therapeutic target
Iacobellis, G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.004 · Cited by 104 · cited 1×
“Clinically, given its rapid metabolism, organ fat specificity and simple measurability, EAT can serve as a modifiable risk factor and therapeutic target for pharmaceutical agents targeting the fat [4].”
BackgroundSelf-citationLima-Martínez, M. M., Paoli, M., Rodney, M., Balladares, N., Contreras, M., D’Marco, L., & Iacobellis, G. (2016) · Endocrine · doi:10.1007/s12020-015-0710-y · Cited by 92 · cited 1×
“Epicardial fat is an easily measurable risk factor [15, 16] that has shown to significantly respond to thiazolidinediones, insulin, dipeptidyl peptidase-4 inhibitors and statins [17-19].”
BackgroundSelf-citationGlucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84 · cited 2×
“We know that GLP-1R is expressed in the adipose tissue and mRNA and protein expression is higher in visceral fat [8, 21].”
BackgroundGLP2: an underestimated signal for improving glycaemic control and insulin sensitivity
Amato, A., Baldassano, S., & Mulè, F. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0035 · Cited by 73 · cited 2×
“Moreover, recent experimental data suggest that glucagon-like peptide 2 (GLP-2) may produce beneficial effects on glucose metabolism in obese animal models [8, 9].”
BackgroundGrosso, A. F., de Oliveira, S. F., Higuchi, M. D. L., Favarato, D., Dallan, L. A. D. O., & da Luz, P. L. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-47 · Cited by 69 · cited 1×
“Some of these drugs caused a significant change and reduction in the EAT inflammatory infiltrate [17].”
BackgroundEpicardial Adipose Tissue and Intracoronary Adrenomedullin Levels in Coronary Artery Disease
Iacobellis, G., di Gioia, C. R., Di Vito, M., Petramala, L., Cotesta, D., De Santis, V., Vitale, D., Tritapepe, L., & Letizia, C. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1231081 · Cited by 67 · cited 1×
“Due to its peculiar anatomical contiguity to the myocardium and bio-genetic features, EAT is thought to play an active role in CAD and diabetes-related atherosclerosis [3].”
BackgroundSelf-citationHighly efficient method for isolation of total RNA from adipose tissue
Cirera, S. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-472 · Cited by 62 · cited 1×
“RNA was extracted from the collected adipose tissues as previously reported [10].”
MethodEpicardial Fat in Atrial Fibrillation and Heart Failure
Iacobellis, G., Zaki, M., Garcia, D., & Willens, H. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1367078 · Cited by 56 · cited 1×
“Epicardial fat is an easily measurable risk factor [15, 16] that has shown to significantly respond to thiazolidinediones, insulin, dipeptidyl peptidase-4 inhibitors and statins [17–19].”
BackgroundSelf-citationGLP‐2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet
Baldassano, S., Rappa, F., Amato, A., Cappello, F., & Mulè, F. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25039 · Cited by 50 · cited 2×
“GLP-2R knockout animals show impaired postprandial glucose tolerance and hepatic insulin resistance [24].”
BackgroundElisha, B., Azar, M., Taleb, N., Bernard, S., Iacobellis, G., & Rabasa-Lhoret, R. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1554688 · Cited by 32 · cited 1×
“Epicardial fat is an easily measurable risk factor [15, 16] that has shown to significantly respond to thiazolidinediones, insulin, dipeptidyl peptidase-4 inhibitors and statins [17-19].”
BackgroundSelf-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“These recent studies include the finding of the receptor in differentiating mouse 3T3-L1 pre-adipocytes [382e384], adipocytes formed from human bone marrow-derived mesenchymal stem cells [385], human epicardial fat [386], and in human visceral white adipose tissue [387].”
BackgroundEpicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797
Self-citationRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Iacobellis, G., & Villasante Fricke, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz042 · Cited by 168
“Immunofluorescence clearly confirmed the presence of GLP-1R protein within EAT, whereas the signal was absent in the subcutaneous fat sample obtain from the same patient [18].”
BackgroundMethodInfluentialSelf-citationAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Metadata
- Authors
- Iacobellis, G., Camarena, V., Sant, D., & Wang, G.
- Affiliations
- University of Miami (US)
- Corresponding author
- Iacobellis, Gianluca
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2017-05-17
- Volume
- 49
- Issue
- 08
- Pages
- 625-630
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- PMC
- PMC7430146
- OpenAlex
- W2614739807
- Cited by
- 112
- References
- 24
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 15 · 2023: 15 · 2022: 15 · 2021: 9 · 2020: 14 · 2019: 8 · 2018: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (T32EY023194)
- National Institute of Neurological Disorders and Stroke (R01NS089525)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- epicardial adipose tissue, GLP-1 receptor, GLP-2 receptor, glucagon-like peptide-1 analogues, GLP-2 analog, subcutaneous adipose tissue, gene expression, coronary artery disease, type 2 diabetes, cardiac surgery, RNA sequencing
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Adipose Tissue, Diabetes Mellitus, Type 2, Female, Gene Expression Regulation, Humans, Male, Pericardium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.